BioStock Studio: Xintela expands to venous leg ulcers

Xintela has broadened the clinical development of its stem cell product XSTEM to include venous leg ulcers, the most common form of difficult-to-heal wounds in humans. Together with the Burn Centre at Linköping University Hospital, the company has shown that XSTEM provides good wound healing in a preclinical model. The next step for the company will be to apply for a clinical study in patients with venous leg ulcers, a study that Professor Folke Sjöberg from the Burn Centre tells us more about below.

Watch the interview with Professor Folke Sjöberg at biostock.se:

https://www.biostock.se/en/2021/10/biostock-studio-xintela-expands-to-venous-leg-ulcers/

This is a press release from BioStock - Connecting Innovation & Capital.